BIONTECH SE ADR
BIONTECH SE ADR
Aktie · US09075V1026 · BNTX · A2PSR2 (XFRA)
Übersicht Finanzkennzahlen
96,35 EUR
0,77 % 0,74 EUR
Schlusskurs XFRA 06.06.2025: 97,10 EUR
Frankfurt (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 13:35

Aktuelle Kurse von BIONTECH SE ADR

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
BNTX
USD
06.06.2025 13:35
110,00 USD
110,15 USD
-0,14 %
XFRA: Frankfurt
Frankfurt
22UA.F
EUR
06.06.2025 13:29
97,10 EUR
97,75 EUR
-0,66 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,86 % 14,12 % 8,13 % -9,36 % -14,33 % 2,61 % 121,20 %

Firmenprofil zu BIONTECH SE ADR Aktie

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Investierte Fonds

Folgende Fonds haben in investiert: BIONTECH SE ADR investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
862,43
Anteil (%)
2,02 %

Unternehmensdaten

Name BIONTECH SE ADR
Firma BioNTech SE
Symbol BNTX
Website https://www.biontech.de
Heimatbörse XFRA Frankfurt
WKN A2PSR2
ISIN US09075V1026
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Ugur Sahin M.D.
Marktkapitalisierung 21 Mrd.
Land Deutschland
Währung EUR
Mitarbeiter 6,8 T
Adresse An der Goldgrube 12, 55131 Mainz
IPO Datum 2019-10-11

Ticker Symbole

Name Symbol
Frankfurt 22UA.F
NASDAQ BNTX
XETRA 22UA.DE

Weitere Aktien

Investoren die BIONTECH SE ADR die halten, haben auch folgende Aktien im Depot:
ALIBABA GR. SP.ADR 8
ALIBABA GR. SP.ADR 8 Aktie
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Aktie
AMAZON.CO INC
AMAZON.CO INC Aktie
APPLE INC
APPLE INC Aktie
BAYER AG     21/29
BAYER AG 21/29 Anleihe
ESB FINANCE 23/43 MTN
ESB FINANCE 23/43 MTN Anleihe
FIDEL.FDS-GL.DIV.AQINCGEO
FIDEL.FDS-GL.DIV.AQINCGEO Fonds
META PLATFORMS INC
META PLATFORMS INC Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
NVIDIA CORP
NVIDIA CORP Aktie
PAYPAL INC
PAYPAL INC Aktie
SQUARE INC A
SQUARE INC A Aktie
TESLA INC
TESLA INC Aktie
VANGUARD VALUE INDEX FUND ETF SHARES
VANGUARD VALUE INDEX FUND ETF SHARES Fonds
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025